Clinical trials: Acellular Pertussis
Diphtheria, Tetanus
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents
This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents. The purposes of this study are as follows: To confirm the non-inferiority of BK1301 to Adsorbed…
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT02118961
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301), Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)
- Where
- 7 sites in Japan
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Diphtheria, Tetanus and Pertussis
Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish Children
Primary objective: This is a descriptive study and the primary objective is to determine the incidence of injection site and systemic adverse events after Triaxis administration as a 5th dose of tetanus, diphtheria and acellular…
- Trial name
- NCT01583049
- Where
- 22 sites in Spain
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®
Primary Objectives: 1. To present the safety profile after a 5th dose of DAPTACEL® in children 4 to 6 years of age who have previously received 4 doses of DAPTACEL® or Pentacel™. 2.
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT00258895
- Testing
- DAPTACEL®: DTaP
- Where
- 22 sites in United States
- Volunteers
- 649 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria-Tetanus-acellular Pertussis Vaccines
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
The purpose of this study is to assess the immunogenicity and safety of Boostrix™ when compared to a placebo given during 27-36 weeks of gestation in healthy women aged 18-45 years.
- Trial name
- NCT02377349
- Testing
- Boostrix™
- Where
- 35 sites in Australia, Canada and 4 more
- Volunteers
- 688 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
The purpose of this study was to evaluate the reactogenicity, safety and immune response of a single intramuscular dose of the respiratory syncytial virus maternal (RSV MAT) vaccine in healthy non-pregnant girls 9-17 years of age…
- Trial name
- NCT05169905
- Testing
- RSV MAT vaccine, dTpa vaccine
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis
Gambia Pertussis Study (GaPs)
Currently, there are two types of vaccines available against pertussis (whooping cough), an infectious disease of the respiratory tract that can be extremely serious in very young children.
- Trial name
- GaPs (NCT03606096)
- Testing
- Boostrix IPV infant acellular Pertussis, Boostrix IPV infant whole Pertussis, TT infant acellular Pertussis
- Where
- The Gambia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers)
A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada
The primary objectives of this study are: To describe the safety profile of each of the investigational vaccine formulations for all participants To describe the humoral and cell-mediated immune responses to all of the…
- Conditions
- Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers), Pertussis Immunisation (Healthy Volunteers)
- Trial name
- NCT03958799
- Testing
- Investigational Tdap vaccine Formulation B, Investigational Tdap vaccine Formulation C, Investigational Tdap vaccine Formulation A
- Where
- 5 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis A Virus
Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)
This two-stage study evaluates the immunogenicity, safety, and tolerability of the administration of VAQTA™ (Hepatitis A Vaccine, Inactivated) concomitantly with PedvaxHIB™ (Haemophilus B Conjugate Vaccine [Meningococcal Protein…
- Trial name
- NCT00289913
- Testing
- Comparator: VAQTA™, Comparator: Infanrix™, Comparator: PedvaxHIB™
- Volunteers
- 1,274 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pertussis Vaccine
Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults
This pivotal safety trial aims to extend the safety database for BioNet recombinant acellular pertussis (aP) vaccine (Pertagen®) in a larger population of adults and evaluate the incidence and characteristics of adverse drug…
- Trial name
- PertaSafe (NCT06798831)
- Testing
- Pertussis containing vaccine
- Where
- 3 sites in Thailand
- Volunteers
- 2,399 people, healthy volunteers welcome
- Sponsor
- BioNet-Asia Co., Ltd.
Acellular Pertussis, Poliomyelitis
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another…
- Conditions
- Acellular Pertussis, Poliomyelitis, Diphtheria, Tetanus
- Trial name
- NCT01323959
- Testing
- BoostrixTM Polio
- Where
- 15 sites in France, Germany
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Diphtheria
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00287092
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, Infanrix® -IPV+Hib
- Where
- 14 sites in Finland, Sweden
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Acellular Pertussis
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety
The aims of this study are to compare the immunogenicity and safety of the GSK Biologicals' combined DTaP-IPV vaccine with separate administration of DTaP and IPV vaccines, when administered as a fifth dose of acellular pertussis…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00263692
- Testing
- Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
- Where
- 15 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in pregnant individuals when taken together at the…
- Conditions
- RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy, Healthy
- Trial name
- CosTaR (NCT07097012)
- Testing
- Tdap Vaccine Administration, RSV Vaccine
- Where
- 4 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Canadian Immunization Research Network
Tetanus, Diphtheria
An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster
Open-label, randomized, multi-centre study in which 400 subjects, divided into two groups, will receive Td5ap or Td1aP as a single injection.
- Conditions
- Tetanus, Diphtheria, Pertussis
- Trial name
- Tdap Booster (NCT00870350)
- Testing
- Td5ap, Td1aP
- Where
- Sweden
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Vaccine Reaction
Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children
This study is to evaluate the immunogenicity and safety of DTaP or DT given in children aged 6 years.
- Trial name
- DTaP/DT (NCT05870618)
- Testing
- vaccinate with DTap, vaccinate with DT
- Where
- 2 sites in China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Diphtheria, Tetanus
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
The purpose of this study is to evaluate the immune response, safety and reactogenicity after receiving combined DTPa-IPV/Hib vaccine when administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02858440
- Testing
- Infanrix-IPV/Hib
- Where
- 5 sites in Russia
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, diphtheria is an acute upper respiratory infectious disease caused by Gram-positive Corynebacterium diphtheriae, and tetanus is a highly fatal…
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT06056050
- Testing
- Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp), 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）, Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Apnea, Apnea Neonatal
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
A prospective, randomized open-label clinical trial will be conducted from July 2018 to October 2020. Approximately 300 preterm infants will be enrolled across three sites: Duke University Medical Center, the University of North…
- Conditions
- Apnea, Apnea Neonatal, Prematurity
- Trial name
- NCT03530124
- Testing
- PCV13, DTaP, HBV
- Where
- 4 sites in United States
- Volunteers
- 223 people
- Sponsor
- Duke University
Pertussis, Tetanus
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
It is well recognized that older adults can contract pertussis, suffer its complications, and unwittingly transmit it to close contacts, which may well include infants too young to have received their primary series of DTaP…
- Conditions
- Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00457249
- Testing
- ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
- Where
- 19 sites in United States
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Sanofi
Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular Pertussis (Tdap)
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
A study team with extensive experience in immunization delivery research will evaluate the effectiveness of vaccination reminder/recall systems for adolescent patients in five types of clinical settings including: urban…
- Conditions
- Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular Pertussis (Tdap), Meningococcal Infection, Varicella
- Trial name
- NCT00715234
- Testing
- Reminder/recall notices for vaccines
- Volunteers
- 4,807 people
- Sponsor
- University of Colorado, Denver